Skip to Main Content

Retroviral

Animal-origin-free proteins for every step of Retroviral manufacturing.

From packaging cell expansion to cryopreservation, recombinant albumin, transferrin and insulin-transferrin supplements replace fetal bovine serum and plasma-derived albumin, lowering variability from cell culture to frozen storage.

Where InVitria proteins fit in Retroviral Manufacturing

Retroviral vector production depends on proteins twice. Packaging cells need iron, insulin and albumin to grow without serum, and the enveloped, thermolabile particles they release need a carrier protein through harvest, filtration, fill and freezing. Fetal bovine serum, serum-derived transferrin and plasma-derived albumin supply those functions with animal- or human-derived raw material and donor-pool variability. Defined, animal-origin-free recombinant proteins supply the same functions, step by step.

Where our products fit

The Retroviral workflow, step by step.

Select a step to see where InVitria products fit.

Producer/Packaging Cell Expansion

Expand stable retroviral packaging cells to production-ready density, with defined, animal-origin-free supplements supporting consistent, serum-free growth.

Overview

Producer/packaging cell expansion grows the stable cell line that constitutively expresses gag-pol and envelope, and in many processes also carries the integrated transfer vector, up to the density and viability required for vector production. Lines such as PG13, PA317, or GP2-293 are expanded in adherent or suspension culture in serum-free or chemically defined medium.

Because these lines already carry the genetic elements needed for vector production, expansion is largely a proliferation step: sustained growth requires iron for DNA synthesis and mitochondrial respiration, and serum-free formats must supply the growth-supporting functions serum otherwise provides through defined additives.

Defined, animal-origin-free versions of these components support predictable growth kinetics and keep the cell substrate free of human- and animal-derived material as the line is expanded toward the production phase, where continuous vector secretion begins.

Constitutive stable packaging lines are harvested directly by repeated supernatant collection (no transfection). Inducible producer lines instead require an induction step (e.g., doxycycline, often with a sodium-butyrate boost) before production.

Functions

Cell Expansion Support

Stable packaging cells expanded in serum-free medium lose the growth factors, iron carrier, and albumin serum otherwise supplies. Insulin supports glucose uptake and anabolic metabolism, transferrin delivers iron for DNA synthesis and mitochondrial function, selenium supports antioxidant enzyme activity, ethanolamine supports membrane phospholipid synthesis, and albumin buffers cells against handling stress, together supporting proliferation to production-ready density.

Recommendation
ITSE+A Animal-Free®

Five-component 100x supplement of recombinant insulin, recombinant human transferrin, selenium, ethanolamine, and recombinant human albumin for serum-free cell culture.

Commonly replaces
Fetal bovine serum (FBS) supplementation in packaging cell expansion medium.

Iron Transport

Proliferating packaging cells have a high iron requirement to support DNA synthesis, mitochondrial respiration, and ribonucleotide reductase activity. Serum-free medium contains no serum-derived transferrin to deliver iron by receptor-mediated endocytosis, and cells left to rely on free iron take it up poorly and are exposed to iron-driven oxidative stress, constraining growth rate ahead of the production phase.

Recommendation
Optiferrin®

Recombinant human transferrin, lyophilized, for iron delivery in serum-free and chemically defined media.

Commonly replaces
Serum-derived transferrin or synthetic iron chelators in serum-free expansion medium.

Vector Production & Harvest

Support packaging cells through continuous vector budding, with defined albumin and transferrin protecting cell health and vector particles through repeated harvest.

Overview

Because retroviral packaging and producer lines constitutively express the genes needed for vector assembly, vector production does not require a separate transient transfection step: cells continuously bud vector particles from the plasma membrane into the culture supernatant once they reach production density. Supernatant is collected on a repeated or continuous schedule, often daily, over the production run.

Retroviral particles are enveloped, shear-sensitive, and notably thermolabile, losing infectious titer within hours at 37°C, which makes rapid, low-stress collection more important than for more stable enveloped vectors. Producer cells continue to require iron throughout the production run to sustain output across repeated harvests.

Defined albumin protects budded vector particles and stressed producer cells during each collection, while defined transferrin continues supporting cell metabolic function, both in animal-origin-free form across the production run.

Functions

Cell & Vector Support

Packaging cells continuously bud vector particles across a production run, and the enveloped, thermolabile particles themselves are shear-sensitive and prone to nonspecific adsorption onto culture-vessel and harvest-line surfaces during each repeated collection. A protein in the supernatant buffers cells against ongoing handling stress and limits vector loss to surfaces during collection, supporting both cell viability and vector recovery across repeated harvests.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Human serum albumin (HSA) or serum supplementation during production culture.

Iron Transport

Packaging cells continuously synthesize viral structural proteins and package vector RNA across the production run, sustaining a high iron requirement for DNA replication and mitochondrial respiration over an extended harvest schedule. Serum-free supernatant carries no serum-derived transferrin, and cells that lose access to protein-bound iron transport lose viability and vector output as repeated harvests continue.

Recommendation
Optiferrin®

Recombinant human transferrin, lyophilized, for iron delivery in serum-free and chemically defined media.

Commonly replaces
Serum-derived transferrin in production-phase culture medium.

Clarification

Clarify each harvested supernatant by filtration or centrifugation, with defined albumin limiting vector loss to filter and surface adsorption.

Overview

Clarification removes packaging cells, cell debris, and aggregates from each harvested batch of vector supernatant, typically by low-speed centrifugation followed by depth filtration, or depth filtration alone in closed processing formats. Because retroviral vector loses titer quickly at ambient and body temperature, clarification is generally performed promptly after each harvest and kept cold.

Retroviral particles are enveloped, thermolabile, and present at relatively low concentration in crude supernatant, and they adsorb nonspecifically to filter membranes, tubing, and vessel surfaces, particularly under the low-protein-concentration conditions typical of clarified harvest.

A defined, animal-origin-free protein in the clarification pool competes for these binding sites, limiting vector loss to surfaces and helping preserve titer as material moves into nuclease treatment and purification.

Functions

Anti-Adsorption

Enveloped, thermolabile retroviral particles are present at low concentration in clarified supernatant and adsorb nonspecifically to depth filter media, tubing, and vessel surfaces, a loss mechanism that becomes proportionally larger as particle concentration drops. A carrier protein in the pool occupies available binding surface, limiting particle-to-surface adsorption and helping preserve infectious titer as material passes through clarification.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Human serum albumin (HSA) or serum-based blocking agents in clarification buffers.

Nuclease Treatment

Treat clarified harvest with an endonuclease to digest residual host-cell nucleic acid ahead of purification.

Overview

Nuclease treatment digests residual host-cell genomic DNA and RNA that remain in clarified retroviral vector harvest, released from packaging cells during production and harvest handling. An endonuclease, most commonly Benzonase, is added directly to the clarified pool and incubated under controlled temperature, pH, and time, typically with magnesium supplementation the enzyme requires for activity.

Benzonase nonspecifically cleaves double- and single-stranded DNA and RNA into short oligonucleotide fragments, reducing residual host-cell nucleic acid to the low levels regulatory guidance requires per dose and reducing the viscosity that high-molecular-weight host-cell DNA otherwise imparts to the pool.

Digestion is typically confirmed by residual DNA assay (such as qPCR against the packaging cell genome) before the pool proceeds to purification. Reduced viscosity and DNA content also improve the performance of downstream chromatography and filtration steps.

Purification (TFF ± Centrifugation)

Purify vector from host-cell protein, DNA, and process contaminants by chromatography, with defined albumin limiting vector loss to resin and system surfaces.

Overview

Purification separates retroviral vector particles from host-cell protein, residual DNA fragments, and other process-related impurities. Common approaches include anion-exchange or membrane chromatography and, where a suitable ligand is available for the envelope glycoprotein, affinity methods; tangential flow filtration (TFF) is often used alongside chromatography for volume reduction and buffer exchange between steps.

Vector at this stage remains dilute, enveloped, and thermolabile, making it susceptible to loss through nonspecific adsorption to chromatography resin, membranes, and flow-path surfaces, as well as to shear during pumping and filtration and to titer decay if processing runs long or warm.

A defined, animal-origin-free protein added to purification buffers limits surface loss and supports recovery through chromatography and TFF as the pool is prepared for concentration and formulation, processed promptly and kept cold throughout.

Functions

Anti-Adsorption

Retroviral particles remain dilute, enveloped, and thermolabile through chromatography and TFF, and their large hydrodynamic size and lipid envelope make them prone to nonspecific adsorption onto resin, membrane, and flow-path surfaces, as well as to shear-driven envelope disruption during pumping. A carrier protein in process buffers occupies binding surface and buffers particles against these losses, supporting recovery through purification.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Human serum albumin (HSA) supplemented into chromatography and TFF process buffers.

Concentration & Buffer Exchange (TFF / UF-DF)

Concentrate vector by TFF and exchange into final buffer, with defined albumin protecting particles against membrane shear and surface loss.

Overview

Concentration and buffer exchange reduce the purified vector pool to final process volume and exchange it into the buffer used for formulation, typically by tangential flow filtration against a membrane with a molecular weight cutoff well below the size of an intact retroviral particle.

TFF exposes vector particles to recirculation shear and extended contact with the filtration membrane surface, and the enveloped, thermolabile particle is sensitive to both; diafiltration also transiently changes the ionic and osmotic environment around the particle as buffer is exchanged.

A defined, animal-origin-free protein in the retentate buffers particles against membrane shear and limits adsorptive loss to the membrane surface, supporting titer recovery into the buffer used for fill and formulation.

Functions

Vector Protection

Tangential flow filtration exposes vector particles to sustained recirculation shear and extended contact with the filtration membrane surface, both of which threaten the integrity of the lipid envelope and drive nonspecific particle adsorption to the membrane. A carrier protein in the retentate buffers particles against this shear and competes for membrane binding sites, supporting titer recovery as the pool is concentrated and exchanged into formulation buffer.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Human serum albumin (HSA) supplemented into TFF retentate and diafiltration buffers.

Sterile / Bioburden Filtration

0.22 um bioburden-reduction filtration ahead of fill. For enveloped, shear-sensitive vectors this is a high-loss step; recombinant albumin protects titer.

Overview

Enveloped, shear- and adsorption-sensitive vectors (lentiviral, gamma-retroviral) lose significant titer on sterilizing-grade membranes. A 0.22 um filtration is performed before or at formulation; pre-coating the membrane with recombinant albumin and including it in the buffer passivates the membrane and buffers the vector against shear and aggregation, preserving infectious and genomic titer.

Functions

Filtration Titer Protection

Sterilizing filtration is typically the single highest-loss operation for enveloped vectors; a passivating protein on the membrane and in the buffer limits vector adsorption, shear, and aggregation loss.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Plasma-derived HSA used as a filtration/stabilization additive.

Sterile Fill & Formulation

Formulate concentrated vector and sterile-filter into final containers, with defined albumin stabilizing particles against freeze-thaw and surface loss.

Overview

Sterile fill and formulation prepares the concentrated, buffer-exchanged vector pool for final containers. The pool is formulated with excipients that protect particle integrity through freezing and storage, sterile-filtered (commonly 0.22 micron), and filled into vials or bags under aseptic conditions.

Formulation is the last opportunity to protect the particle before it is frozen: retroviral vector is enveloped, thermolabile, and freeze-thaw sensitive, and dilute vector is prone to aggregation and adsorptive loss to container and closure surfaces during fill.

A defined, animal-origin-free stabilizing excipient in the formulation buffer limits this loss and supports vector recovery through freezing, in liquid or, where a dry formulation workflow is used, lyophilized form.

Functions

Formulation Stabilization

Formulated vector is dilute relative to production-scale concentrations, enveloped, and thermolabile, making it susceptible to aggregation and to adsorptive loss on container, closure, and fill-line surfaces during sterile filtration and filling. A stabilizing excipient occupies these surfaces and buffers particles against the freeze-thaw stress that follows fill, supporting recovered infectious titer at the point of use.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Human serum albumin (HSA) as a stabilizing excipient in viral vector formulation buffers.

Cryopreservation & Storage

Cryopreserve filled vector for long-term storage, with defined albumin protecting particles against freeze-thaw and container-surface loss.

Overview

Cryopreservation and storage hold finished retroviral vector at low temperature, typically -80°C or below, to maintain infectious titer between fill and use. Filled containers are frozen under controlled conditions and held in qualified freezer or vapor-phase nitrogen storage.

Freezing and thawing subject enveloped, thermolabile vector particles to ice-crystal formation, osmotic shifts, and mechanical stress, and dilute vector remains susceptible to adsorptive loss on vial or bag surfaces throughout storage. Repeated freeze-thaw cycling compounds this loss.

A defined, animal-origin-free stabilizing excipient carried through from formulation continues protecting the particle during freezing, storage, and thaw, supporting infectious titer at the point the vector is used.

Functions

Storage Stabilization

Freezing exposes vector particles to ice-crystal formation and osmotic shifts, and thaw repeats that stress in reverse; dilute, enveloped, thermolabile vector is also prone to continued adsorptive loss on container surfaces across a storage hold. A stabilizing excipient carried through from formulation buffers particles against this cycle, limiting loss of infectious titer between fill and administration.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Human serum albumin (HSA) as a cryoprotective excipient in viral vector storage formulations.